Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-091776
Filing Date
2024-08-06
Accepted
2024-08-06 16:05:50
Documents
60
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q spry-20240630.htm   iXBRL 10-Q 2060690
2 EX-10.1 spry-ex10_1.htm EX-10.1 21551
3 EX-31.1 spry-ex31_1.htm EX-31.1 14249
4 EX-31.2 spry-ex31_2.htm EX-31.2 14223
5 EX-32.1 spry-ex32_1.htm EX-32.1 16242
  Complete submission text file 0000950170-24-091776.txt   7024416

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spry-20240630.xsd EX-101.SCH 1077874
62 EXTRACTED XBRL INSTANCE DOCUMENT spry-20240630_htm.xml XML 933260
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39756 | Film No.: 241179128
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)